The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania

Bibliography

• Product Information Saphris® (asenapine) sublingual tablets. Initial US approval: 2009
   Google Scholar
• Tarazi FI, Shahid M. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today 2009;45:865-76
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 2012;13:1911-22
   PubMed Web of Science ®Google Scholar
• Szegedi A, Calabrese JR, Stet L, Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46-55
   PubMed Web of Science ®Google Scholar
• Peeters PAM, Bockbrader H, Spaans E, Asenapine pharmacokinetics: influence of hepatic and renal impairment [Abst NR4-081]. 161st Amer Psychiatric Assoc; 3 – 8 May; Washington DC; 2008
   Google Scholar
• Chapel S, Hutmatcher M, Haig G, Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine, quetiapine, or placebo administration on QTc prolongation. J Clin Psychopharmacol 2009;49:1297-308
   Web of Science ®Google Scholar
• Shahid M, Walker GB, Zorn SH, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Li Z, Kaneda Y, Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Roy A, A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-85
   PubMed Web of Science ®Google Scholar
• Ghanbari R, El Mansari M, Shahid M, Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha2 and D2 receptors in the rat brain. Eur Neuropsychopharmacol 2009;19:177-87
   PubMed Web of Science ®Google Scholar
• Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;288:774-81
   PubMed Web of Science ®Google Scholar
• Zhang W, Perry KW, Wong DT, Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-62
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Dai J, O'Laughlin IA, Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002;26:325-39
   PubMed Web of Science ®Google Scholar
• Assié MB, Ravailhe V, Faucillon V, Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005;315:265-72
   PubMed Web of Science ®Google Scholar
• Huang M, Li Z, Dai J, Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008;33:2934-45
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005;57:1377-84
   PubMed Web of Science ®Google Scholar
• Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther 2005;27(Suppl A):S25-37
   PubMed Web of Science ®Google Scholar
• Millan MJ, Dekeyne A, Gobert A. Serotonin 5-HT2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998;37:953-5
   PubMed Web of Science ®Google Scholar
• Owen JC, Whitton PS. Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of alpha2 and 5-HT1A receptors. Neurosci Lett 2003;348:171-4
   PubMed Web of Science ®Google Scholar
• Devoto P, Flore G, Pira L, Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. J Neurochem 2004;88:1003-9
   PubMed Web of Science ®Google Scholar
• Frånberg O, Wiker C, Marcus MM, Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-29
   PubMed Web of Science ®Google Scholar
• Deutch AY. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm 1993;91:197-221
   PubMed Web of Science ®Google Scholar
• Marcus MM, Nomikos GG, Svensson TH. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol 1996;6:29-38
   PubMed Web of Science ®Google Scholar
• Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992;3:332-41
   PubMed Web of Science ®Google Scholar
• Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998;12(1-2):21-36
   PubMed Web of Science ®Google Scholar
• Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill; New York; 2005. p. 461-500
   Google Scholar
• Tarazi FI, Moran-Gates T, Wong EH, Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 2008;198:103-11
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Yeghiayan SK, Baldessarini RJ, Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology 1997;17:186-96
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001;297:711-17
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS, Castner SA, Svensson TH, Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004;174:3-16
   PubMed Web of Science ®Google Scholar
• Fleming K, Potkin SG, Binneman B, Asenapine improves cognitive function in acute schizophrenia: A placebo- and risperidone-controlled trial [Abst NR513]. 160th Amer Psychiatric Assoc; 19 –24 May; San Diego, CA; 2007
   Google Scholar
• Marin C, Parashos SA, Kapitzoglou-Logothetis V, D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 1993;45:195-200
   PubMed Web of Science ®Google Scholar
• Parashos SA, Marin C, Barone P, Effect of chronic D1 and/or D2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology (Berl) 1990;102:411-13
   PubMed Web of Science ®Google Scholar
• Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997;280:561-9
   PubMed Web of Science ®Google Scholar
• Lidow MS, Goldman-Rakic PS. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 1997;283:939-46
   PubMed Web of Science ®Google Scholar
• Krieckhaus EE, Donahoe JW, Morgan MA. Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry 1992;31:560-70
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Moran-Gates T, Wong EH, Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2010;24:341-8
   PubMed Web of Science ®Google Scholar
• Kuoppamaki M, Seppala T, Syvalahti E, Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 1993;264:1262-7
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002;161:263-70
   PubMed Web of Science ®Google Scholar
• Diaz-Mataix L, Scorza MC, Bortolozzi A, Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005;25:10831-43
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45
   PubMed Web of Science ®Google Scholar
• Kane JM, Cohen M, Zhao J, Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30:106-15
   PubMed Web of Science ®Google Scholar
• Burnet PW, Chen CP, McGowan S, The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 1996;73:531-40
   PubMed Web of Science ®Google Scholar
• Rauser L, Savage JE, Meltzer HY, Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor. J Pharmacol Exp Ther 2001;299:83-9
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004;26:1936-46
   PubMed Web of Science ®Google Scholar
• Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-500
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Choi YK, Gardner M, Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63:413-20
   PubMed Web of Science ®Google Scholar
• Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 2000;31:302-12
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Holm-Waters S, Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol 2001;41:237-60
   PubMed Web of Science ®Google Scholar
• Choi YK, Wong EH, Henry B, Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010;13:405-10
   PubMed Web of Science ®Google Scholar
• Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1145-58
   PubMed Web of Science ®Google Scholar
• Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 2004;174:25-31
   PubMed Web of Science ®Google Scholar
• Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 2008;107:1188-95
   PubMed Web of Science ®Google Scholar
• Salmi P, Samuelsson J, Ahlenius S. A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. J Pharmacol Toxicol Methods 1994;32:155-9
   PubMed Web of Science ®Google Scholar
• Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999;23:851-62
   PubMed Web of Science ®Google Scholar
• Castagné V, Moser PC, Porsolt RD. Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol 2009;57:381-418
   PubMedGoogle Scholar
• Marston HM, Young JW, Martin FD, Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 2009;206:699-714
   PubMed Web of Science ®Google Scholar
• Braff DL. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci 2010;4:349-71
   PubMedGoogle Scholar
• Geyer MA, Krebs-Thomson K, Braff DL, Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001;156:117-54
   PubMed Web of Science ®Google Scholar
• Auclair AL, Kleven MS, Besnard J, Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 2006;31:1900-9
   PubMed Web of Science ®Google Scholar
• Ahlenius S, Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 1986;24:1409-15
   PubMed Web of Science ®Google Scholar
• Wadenberg ML, Soliman A, VanderSpek SC, Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001;25:633-41
   PubMed Web of Science ®Google Scholar
• Klein D. Depression and anhedonia. In: Clark C, Fawcett J, editors. Anhedonia and affect deficit states. PMA Publishing; New York, NY: 1984
   Google Scholar
• Papp M, Moryl E, Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 1996;296:129-36
   PubMed Web of Science ®Google Scholar
• Papp M, Panconi E, Gruca P. Effects of the novel antidepressant milnacipran in a chronic mild stress model of depression. Drug Develop Res 2004;61:101-6
   Web of Science ®Google Scholar
• Papp M, Wieronska J. Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol 2000;14:46-52
   PubMed Web of Science ®Google Scholar
• Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997;134:319-29
   PubMed Web of Science ®Google Scholar
• Marston HM, Martin FD, Papp M, Attenuation of chronic mild stress-induced ‘anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation. J Psychopharmacol 2011;25:1388-98
   PubMed Web of Science ®Google Scholar
• Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441-60
   PubMed Web of Science ®Google Scholar
• Mnie-Filali O, Faure C, Lambás-Señas L, Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011;36:1275-88
   PubMed Web of Science ®Google Scholar
• Szegedi A, Zhao J, van Willigenburg A, Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011;11:101
   PubMed Web of Science ®Google Scholar
• Keefe RS, Sweeney JA, Gu H, Effects of olanzapine, quetiapine, and risperidone on neurocognition function in early psychosis: a randomised, double-blind 52-week comparison. Am J Psychiatry 2007;164:1061-71
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Keefe RS, Umbricht D, The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 2011;37:1209-17
   PubMed Web of Science ®Google Scholar
• Neill JC, Barnes S, Cook S, Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 2010;128:419-32
   PubMed Web of Science ®Google Scholar
• Snigdha S, Idris N, Grayson B, Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) 2011;214:843-53
   PubMed Web of Science ®Google Scholar
• Tait DS, Marston HM, Shahid M, Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacology (Berl) 2009;202:295-306
   PubMed Web of Science ®Google Scholar
• Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set-shifting in the rat. J Neurosci 2000;20:4320-4
   PubMed Web of Science ®Google Scholar
• Pantelis C, Barber FZ, Barnes TRE, Comparison of set shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 1999;37:251-70
   PubMed Web of Science ®Google Scholar
• Saleem MM, Harte MK, Marshall KM, Investigation into cognitive function in first episode psychosis patients. Schizophr Res 2010;117:215
   Web of Science ®Google Scholar
• Paz RD, Tardito S, Atzori M, Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008;18:773-86
   PubMed Web of Science ®Google Scholar
• Elsworth JD, Groman SM, Jentsch JD, Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 2012;62:1442-52
   PubMed Web of Science ®Google Scholar
• McLean SL, Neill JC, Idris NF, Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res 2010;214:240-7
   PubMed Web of Science ®Google Scholar
• Snigdha S, Neill JC. Improvement of phencyclidine induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 2008;191:26-31
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opinion Pharmacol 2011;11:59-67
   PubMed Web of Science ®Google Scholar
• Arnt J, Bang-Andersen B, Grayson B, Lu AE58054, a 5-HT6 antagonist with pro cognitive potential. Int J Neuropsychopharmacol 2010;13:1021-33
   PubMed Web of Science ®Google Scholar
• Idris NF, Neill JC, Grayson B, Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms. Psychopharmacology (Berl) 2010;208:23-36
   PubMed Web of Science ®Google Scholar
• McLean SL, Idris NF, Woolley ML, D1-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 2009;19:440-50
   PubMed Web of Science ®Google Scholar
• Akimova E, Lanzenberger R, Kasper S. The serotonin1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627-35
   PubMed Web of Science ®Google Scholar
• Savitz J, Lucki I, Drevets WC. 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 2009;88:17-31
   PubMed Web of Science ®Google Scholar
• Shelton RC, Osuntokun O, Heinloth AN, Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-61
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, Novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4
   PubMed Web of Science ®Google Scholar
• Tecott LH, Sun LM, Akana SF, Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995;374:542-6
   PubMed Web of Science ®Google Scholar
• Stahl SM. Selective histamine H1 antagonism: Novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 2008;13:1027-38
   PubMed Web of Science ®Google Scholar